Stock INVA INNOVIVA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Innoviva, Inc.

Equities

INVA

US45781M1018

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
15.26 USD +1.80% Intraday chart for Innoviva, Inc. +2.07% -4.86%
Apr. 24 Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc.?s Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024 CI
Mar. 04 Armata Pharmaceuticals Secures $35 Million Credit Agreement From Innoviva Unit MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Innoviva Specialty Therapeutics Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
AQ
Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
BU
Innoviva: Q4 Earnings Snapshot
AQ
Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress
BU
Innoviva Specialty Therapeutics Appoints David Altarac, MD, as Chief Medical Officer
AQ
Innoviva Specialty Therapeutics - Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea
AQ
Innoviva: Q3 Earnings Snapshot
AQ
Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
BU
Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea
BU
Innoviva Specialty Therapeutics Presents New Data on its Critical Care Antibiotic Therapy Portfolio at Infectious Disease Week 2023
AQ
Innoviva to Participate in the Cantor Global Healthcare Conference
BU
Innoviva - XACDURO, the First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia in Adults
AQ
XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults
BU
Innoviva Appoints Stephen Basso as Chief Financial Officer
AQ
Innoviva Appoints Stephen Basso as Chief Financial Officer
BU
Innoviva: Q2 Earnings Snapshot
AQ
Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
BU
Purcell & Lefkowitz LLP Is Investigating Innoviva, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
PR
Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics
AQ
Innoviva to Participate in the Goldman Sachs Annual Global Healthcare Conference
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. INVA Stock
  4. News Innoviva, Inc.
  5. Press Releases